



Preliminary Data to be Presented Evaluating ^{99m}Tc-Maraciclatiside as a New Imaging Marker for Endometriosis

London, UK, 19th January 2024. Serac Healthcare Limited (“Serac Healthcare” or “the Company”), a clinical radiopharmaceutical company developing an innovative molecular imaging agent, announces that an abstract on the preliminary data from the first cohort of patients in the “Detecting Endometriosis expressed integrins using technetium-99m” imaging (DETECT) study, has been accepted for oral presentation at the Society for Reproductive Investigation (SRI) annual meeting taking place from 12-16 March 2024 in Vancouver, Canada.

Dr Tatjana Gibbons, an investigator on the study, will be presenting on Friday 15th March at 11.45am, as part of the Gynaecology II session running from 11-12.30 pm.

The study is investigating whether it is possible to visualise endometriosis, including superficial peritoneal disease (which cannot be reliably detected using existing non-invasive imaging techniques) using ^{99m}Tc-maraciclatiside and SPECT-CT imaging. The study is being led by Professor Christian Becker, Co-Director of the Endometriosis CaRe Centre in Oxford, together with Professor Krina Zondervan, Head of Department at the Nuffield Department of Women’s and Reproductive Health, University of Oxford. In the first stage of the study, participants were scanned to determine the most appropriate imaging window. A second stage is now underway with participants who will be imaged at a single time point.

^{99m}Tc-maraciclatiside is a radio-labelled tracer which binds with high affinity to the cell adhesion protein $\alpha_v\beta_3$ integrin and images angiogenesis (new blood vessel formation). Clinical trials in a range of conditions, including breast cancer, bone metastases and rheumatoid arthritis, in which angiogenesis plays a key role, have shown the agent to perform as expected and be well tolerated. Angiogenesis is also known to be critical to the establishment and growth of endometriotic lesions.

In the DETECT study, women with confirmed or suspected endometriosis who are due to undergo laparoscopy, a key-hole surgical procedure used to assess the organs in the abdomen and pelvis, are imaged with ^{99m}Tc-maraciclatiside before laparoscopic surgery. During surgery, tissue samples with identified endometriosis are collected and analysed to determine the presence of $\alpha_v\beta_3$. The laparoscopic and radiographic findings are compared to determine whether ^{99m}Tc-maraciclatiside holds potential as a novel, non-invasive method of detecting early-stage endometriosis.

Endometriosis is a common inflammatory disease that affects one in 10 women of childbearing age, about 190 million women worldwide. It occurs when endometrial tissue that lines the uterus is found outside of the uterus, predominantly in the pelvis, e.g. fallopian tubes or ovaries, but can occur elsewhere in the body too, e.g. lungs. The presence of endometrial tissue outside the uterus can lead to inflammation, the development of nerve supply and distortion of normal anatomy, which can cause significant pain and infertility. The diagnostic journey in those with endometriosis typically results in numerous visits to physicians and hospitals, along with multiple scans. Non-invasive diagnostic methods cannot reliably detect the most prevalent form of endometriosis, known as superficial peritoneal disease, which can frequently only be accurately identified through laparoscopic surgery. The limitations in current diagnostic methods have contributed to the average delay of 7.5 years to secure a diagnosis.

David Hail, Chief Executive Officer of Serac Healthcare, said:

“This is a potentially hugely exciting additional use for maraciclatiside. There are significant unmet medical needs in the diagnosis and treatment of endometriosis. A definitive tool to diagnose and monitor endometriosis has the potential to significantly improve patient outcomes, reduce healthcare costs and could assist in the development of new therapies.”

-ENDS-

For more information, please contact:

Serac Healthcare Ltd

www.serachealthcare.com

David Hail, Chief Executive Officer

+44 (0)208 948 0000
info@seraclifesciences.com

Francetta Carr, Communications

+44 (0)7711 010820
francettacarr@seraclifesciences.com

Notes to Editors

About Serac Healthcare Ltd

Serac Healthcare is a clinical radiopharmaceutical company with deep expertise in discovering, developing and commercialising innovative molecular imaging technologies. Using these targeted technologies to underpin personalised medicine in the fields of endometriosis and inflammatory arthritis, Serac Healthcare is focused on bringing to market effective tools to accelerate diagnosis, and to deliver earlier and more effective treatment decisions. Serac Healthcare Ltd is a wholly owned subsidiary of Serac Life Sciences Limited.

Maraciclatiside is for investigational use only and is not approved by the FDA or UK and European regulatory authorities.

About the DETECT study

The study is jointly sponsored by Oxford Endometriosis CaRe Centre and the Nuffield Department of Women's and Reproductive Health, Oxford University, and funded by Serac Healthcare Ltd who are providing the experimental imaging marker ^{99m}Tc-maraciclatiside. Further details are available on ClinicalTrials.gov [here](#).

About the Society for Reproductive Investigation Meeting: www.sri-online.org/meetings-calendar/2024